Multiple Sclerosis Clinical Trial
Official title:
Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis
Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and blinded cross-over trial of dalfampridine of 8 weeks duration The study will test the hypothesis that dalfampridine, when administered to subjects with incomplete visual recovery after optic neuritis from MS, will result in symptomatic improvement in visual function. The study will consist of one screening/baseline visit, one visit during treatment with active drug, and one visit on placebo. After the baseline visit, subjects will be randomly assigned to receive study medication or placebo for the first three weeks, followed by a two week wash-out, and then treatment reallocation for the latter three weeks.
Optic neuritis (ON) is the presenting feature of multiple sclerosis (MS) in 15% of cases, and
occurs over the disease course in 50% of patients.1-3 Vision remains a major concern for MS
patients, as visual dysfunction leads to lower quality of life.4-6 Despite the high
prevalence of ON in MS, treatment and management options remain limited. Although intravenous
glucocorticoids are employed to aid recovery of an acute episode of ON, no convincing
evidence supports their efficacy in altering the degree of long-term recovery.7 Although some
individuals with ON can have a dramatic recovery from blindness, ON often impairs visual
function permanently. In the Optic Neuritis Treatment Trial, 63% reported that vision had not
returned to normal after 6 months, and 20% had vision worse than 20/20 after 5 years of
follow-up.8, 9 Visual impairment creates difficulties at home and work, leading to decreased
independence and impaired mobility within the community. Visual dysfunction in combination
with MS impairments within cerebellar and proprioceptive systems can be particularly
disabling.
Optic neuritis classically impairs one's ability to read print or a computer screen, to drive
in bright or low light, and to appreciate colors and contrasts. Unfortunately, when optic
neuritis results in lasting impairment, there are no pharmacologic therapies to restore
vision. Low vision specialists may provide magnifying glasses, brighter lights, and advice to
optimize the position of objects at home and in the workplace. Better treatment options are
needed to improve visual function.
Ampyra (dalfampridine) is a potassium-channel antagonist, with a mechanism-of-action to
improve nerve conduction in demyelinated axons, resulting in an electrophysiologic and
clinical benefit.10-22 Demyelinated axons within the anterior visual pathway would be a prime
and ideal target to study the effects of Ampyra. In fact, Stefoski et al demonstrated visual
function benefit in an open-label study of IV 4-aminopyridine in 12 subjects.21 The optic
nerves are a well-defined white-matter tract, commonly affected in MS, and with clear
clinical outcome measures. In addition, visual evoked potentials (VEPs) can be included
within the study design as a secondary endpoint, to confirm improved nerve conduction.
Because VEPs are such a precise, reliable, and accepted measure of demyelination, the
anterior visual pathway is the ideal in vivo human system to study the electro-physiologic
effects of a therapeutic such as Ampyra.
Hypothesis 1: Dalfampridine treatment will improve visual function, measured by the 5% ETDRS
contrast sensitivity chart, in subjects with long-term visual impairment secondary to optic
neuritis from MS.
Hypothesis 2: Dalfampridine treatment will reduce visual evoked potential P100 latency
following remote optic neuritis.
Hypothesis 3: Dalfampridine treatment will result in an improvement in secondary endpoints,
including visual fields, high contrast visual acuity, color vision, and quality of life.
The study will be conducted at the Department of Neurology and Neurosurgery, Washington
University School of Medicine, St. Louis, the institution at which Dr. Naismith is based. The
MS patients will come from the 1800 active MS patients in our clinic and the 3500 in the St.
Louis area.
Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and
blinded cross-over trial of dalfampridine of 8 weeks duration (Table 1). The study will test
the hypothesis that dalfampridine, when administered to subjects with incomplete visual
recovery after optic neuritis from MS, will result in symptomatic improvement in visual
function. The study will consist of one screening/baseline visit, one visit during treatment
with active drug, and one visit on placebo. After the baseline visit, subjects will be
randomly assigned to receive study medication or placebo for the first three weeks, followed
by a two week wash-out, and then treatment reallocation for the latter three weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |